Alcohol and Other Depressants
Drugs and Society
Learning objectives for this lesson:
- Explain how alcohol acts on GABA-A and NMDA glutamate receptors and why it is classed as a central nervous system depressant.
- Describe the absorption, distribution, liver metabolism and zero-order elimination of alcohol, and the factors that make blood alcohol differ between people.
- Calculate Canadian standard drinks and estimate a blood alcohol concentration with the Widmark formula, stating the assumptions that limit the estimate.
- Describe Canada’s Guidance on Alcohol and Health (2023) as an example of risk communication.
- Compare benzodiazepines, Z-drugs, barbiturates and GHB in their mechanisms, medical uses, half-lives, risks and legal status in Canada.
- Explain why physical dependence develops with prescribed sedative use, why abrupt withdrawal is dangerous, and what the evidence suggests about deprescribing in older adults.
- Classify inhalants, explain how most of them act as central nervous system depressants, and describe their acute risks and long-term harms, including nerve damage from heavy nitrous oxide use and the rise in its recreational use reported in Europe in 2022.
- Explain why alcohol, benzodiazepines, GHB and opioids taken together suppress breathing, and evaluate the evidence behind rules on co-prescribing opioids and sedatives.
This course was developed by Dr. Kiffer G. Card.
Alcohol as a Drug: Brain Actions, Metabolism and the Standard Drink
Content note
This section mentions alcohol poisoning, including deaths. If you would like support, the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677) and the Hope for Wellness Help Line for Indigenous people (1-855-242-3310) are available at any time.
Introduction
Alcohol is so familiar in Canadian life that it is easy to forget it is a drug. It is sold legally to adults, yet ethanol, the molecule in every beer, cider, wine and spirit, acts on the brain in ways that resemble prescription sedatives. Many young people meet it early: in the 2023–24 Canadian Student Alcohol and Drugs Survey of junior high and high school students in nine provinces (known before that cycle as the Canadian Student Tobacco, Alcohol and Drugs Survey), students first drank alcohol at age 13 on average, and 21% reported high-risk drinking (five or more drinks on one occasion) in the previous 12 months (Health Canada, 2025b).
This section applies the ideas from Lesson 3 (receptors, absorption, metabolism, half-life and tolerance) to alcohol. HSCI 402 develops the health harms of alcohol, fetal alcohol spectrum disorder and alcohol policy.
Learning Objectives
- 1.1 Explain why alcohol is classed as a central nervous system depressant, describing its actions at GABA-A and NMDA glutamate receptors.
- 2.1 Describe how alcohol is absorbed, distributed in body water and metabolized by the liver, explain why its elimination is roughly constant per hour, and identify factors that make blood alcohol differ between people.
- 3.1 Calculate the number of Canadian standard drinks in a container from its volume and its percentage of alcohol.
- 3.2 Estimate a blood alcohol concentration with the Widmark formula and explain the assumptions that limit any such estimate.
- 4.1 Describe Canada’s Guidance on Alcohol and Health (2023) as an example of risk communication.
1.1 Alcohol as a Central Nervous System Depressant
A depressant is a drug that reduces the activity of the central nervous system, the brain and spinal cord. The term describes an effect on nerve cells and says nothing about mood: at low doses a depressant can make a person relaxed or talkative, because it first quiets the brain systems that hold behaviour in check. As the dose rises, the slowing spreads to coordination, memory, consciousness and finally breathing. Every drug in this lesson follows this progression.
1.1.1 GABA and Glutamate: Two Sides of the Same Effect
Two neurotransmitters set much of the brain’s overall level of activity (Lesson 3 introduced neurotransmitters and receptors). Gamma-aminobutyric acid (GABA) is the main inhibitory messenger: when it binds to the GABA-A receptor, a channel opens that lets negatively charged chloride ions into the cell, making the cell less likely to fire. Glutamate is the main excitatory messenger: at the NMDA receptor (named after the chemical N-methyl-D-aspartate), it lets positive ions in and makes the cell more likely to fire (Valenzuela, 1997).
At intoxicating concentrations, alcohol generally enhances GABA-A receptor function and inhibits glutamate receptors, including the NMDA type (Abrahao et al., 2017; Valenzuela, 1997), so inhibition rises and excitation falls, as Figure 4.1 shows. Because NMDA receptors help form new memories, their inhibition may help explain why heavy drinking can disrupt memory for events that happened during intoxication (Valenzuela, 1997).
3-D Model 4.1 shows where these receptors are found in the brain, using maps made with positron emission tomography (PET), a scanning method that measures where an injected radioactive tracer binds, and it highlights the brainstem, which controls breathing, and the hippocampus, which is needed to form new memories.
1.1.2 A Drug with Many Targets
Ethanol is a very small molecule that forms only weak bonds with proteins, so it needs high concentrations to act and has many targets, including glycine receptors and several kinds of potassium channels. It also increases the firing of dopamine neurons in the midbrain, one link to its rewarding effects (Abrahao et al., 2017), which Lesson 8 develops. Pharmacologists therefore describe alcohol as a relatively nonspecific drug. Reviews published in 1997 and 2017 describe the same main receptor actions, although the 2017 review notes that the details of how ethanol interacts with the NMDA receptor are still poorly understood (Valenzuela, 1997; Abrahao et al., 2017).
1.1.3 From Acute Effects to Adaptation
With long-term heavy drinking, GABA-A receptor function falls and glutamate receptors become more active, changes that contribute to tolerance, the need for more of a drug to produce the same effect. If alcohol is suddenly removed, the brain is left with too little inhibition and too much excitation, which contributes to the anxiety and seizures of alcohol withdrawal (Valenzuela, 1997). Section 2 applies the same logic to benzodiazepines, and Lesson 8 develops neuroadaptation in detail. The next part follows alcohol through the body.
2.1 Absorption, Distribution and Metabolism
Each step of alcohol’s pharmacokinetics (what the body does to a drug, Lesson 3) helps explain why two people who drink the same amount reach different blood levels.
2.1.1 Absorption: Why Food Matters
Alcohol is absorbed from the stomach and, more rapidly, from the first parts of the small intestine, so the speed at which the stomach empties is a main control on how fast blood alcohol rises. Food slows emptying, whether a meal is high in fat, carbohydrate or protein, and whether a drink is taken on an empty stomach or with a meal is the major factor governing absorption (Cederbaum, 2012). Some alcohol is broken down in the stomach before it reaches the blood, a process called first-pass metabolism, although its overall importance is debated (Cederbaum, 2012).
2.1.2 Distribution: Alcohol Follows Water
Alcohol spreads through body water and dissolves poorly in fat, so a person with more body water dilutes the same dose into a larger volume. Women, who on average have a higher percentage of body fat, therefore reach higher peak levels than men after the same dose per kilogram of body weight, with no difference when the dose is matched to litres of body water (Cederbaum, 2012).
2.1.3 Metabolism in the Liver
The liver removes most alcohol in two steps, shown in Figure 4.2. The enzyme alcohol dehydrogenase (ADH) converts ethanol into acetaldehyde, a toxic compound, and aldehyde dehydrogenase (ALDH) converts acetaldehyde into acetate, which other tissues use for energy. A second route, the enzyme CYP2E1, is induced (made more active) by chronic heavy drinking; induction contributes to metabolic tolerance and changes how some medicines, including acetaminophen, are processed (Cederbaum, 2012).
Between 15% and 40% of people in East Asia carry an inactive form of the ALDH2 enzyme, so acetaldehyde builds up when they drink and causes flushing and nausea (Cederbaum, 2012); Lesson 9 returns to this variant as a protective factor against alcohol use disorder. The medicine disulfiram blocks ALDH deliberately and produces the same reaction, and HSCI 402 discusses its place in treatment.
2.1.4 Elimination: A Constant Amount per Hour
Lesson 3 described elimination by half-life, in which a constant fraction of a drug is removed in each period of time. Alcohol behaves differently. ADH is saturated after the first few drinks, so the liver removes a roughly constant amount each hour, a pattern called zero-order elimination. Jones (2010) found that blood alcohol falls by about 10 to 15 milligrams per 100 millilitres per hour after drinking on an empty stomach and 15 to 20 after a meal, and by 25 to 35 in people with alcohol dependence whose CYP2E1 activity is boosted; he suggested 15 as a good average for moderate drinkers. At that rate, a level of 80 milligrams per 100 millilitres takes more than five hours to reach zero.
The flip cards below summarize four factors that change the blood alcohol produced by the same drink.
With these processes in place, the next question is how much alcohol a drink contains.
3.1 The Canadian Standard Drink
Containers differ in size and strength, so public health agencies count alcohol in standard drinks, each containing a fixed amount of pure alcohol; definitions range from 8 to 20 grams across countries (Paradis et al., 2023). In Canada, a standard drink is 17.05 millilitres or 13.45 grams of pure alcohol (Health Canada, 2025a), and Table 4.1 lists the reference servings.
Table 4.1. The four reference servings that each contain one Canadian standard drink (Health Canada, 2025a).
| Beverage | Serving | Alcohol content |
|---|---|---|
| Beer | 341 mL (12 oz) bottle | 5% |
| Cider | 341 mL (12 oz) bottle | 5% |
| Wine | 142 mL (5 oz) glass | 12% |
| Spirits | 43 mL (1.5 oz) shot | 40% |
The percentage on a label is the alcohol by volume (ABV). Multiplying the volume by the ABV gives the millilitres of alcohol, and dividing by 17.05 gives the number of standard drinks, as Equation 4.1 shows. Worked example 4.1 applies it to common containers.
Worked example 4.1. A 750 mL bottle of 12% wine holds 750 × 12 ÷ 100 = 90 mL of pure alcohol, or 90 ÷ 17.05 = 5.3 standard drinks. A 473 mL “tall can” of 5% beer holds 23.65 mL, or 1.4 standard drinks, and a 750 mL bottle of 40% spirits holds 300 mL, or about 17.6. Servings can also exceed the reference sizes: an information sheet from the Canadian Institute for Substance Use Research shows that a 9 oz (about 266 mL) glass of 14% wine holds more than two standard drinks (CISUR, 2025). Use Calculator 4.1 to check these figures and to try other containers.
The arithmetic is simple on paper, but it needs information that people may not have at hand when they buy or pour a drink. The expert panel behind Canada’s Guidance on Alcohol and Health suggested that mandatory labelling of all alcoholic beverages with the number of standard drinks in the container could be a particularly effective policy change (Paradis et al., 2023). The last part of this section (4.1 Canada’s Guidance on Alcohol and Health as Risk Communication) returns to that proposal; first, the standard drink supplies the dose for estimating blood alcohol.
3.2 Blood Alcohol Concentration and the Widmark Formula
The blood alcohol concentration (BAC) links the dose a person drinks to its effects. In Canada it is usually given in milligrams of alcohol per 100 millilitres of blood. As of October 2026, the Criminal Code limit for driving is 80 milligrams per 100 millilitres, and it is an offence to have that level within two hours of driving (Department of Justice Canada, 2022). Other countries write the same level as 0.08% or 0.8 grams per litre.
3.2.1 What Different Levels Do
Table 4.2 converts the levels that Abrahao and colleagues (2017) summarized for people who do not drink heavily into Canadian units. The ranges are approximate, and a person with high tolerance can survive levels several times higher.
Table 4.2. Approximate blood alcohol concentrations and their effects in people without tolerance (converted from Abrahao et al., 2017).
| Approximate BAC (mg per 100 mL) | Typical effects |
|---|---|
| About 28 | Effects can be reliably detected. |
| About 55 | Reduced anxiety and euphoria. |
| About 83 | Slowed reaction time, poor coordination and impaired thinking (around the Criminal Code limit of 80). |
| Up to about 230 | Increasing disruption of movement, cognitive impairment and sedation. |
| Above about 230 | Strong sedation and depressed breathing that can lead to coma or death. |
At the top of the table, alcohol poisoning shuts down the brain areas that control breathing, heart rate and body temperature. Its signs include confusion, inability to wake, vomiting, seizures, slow or irregular breathing, a missing gag reflex and a very low body temperature (NIAAA, 2025). Section 4 explains why these risks rise when alcohol is combined with other depressants.
3.2.2 The Widmark Formula
In the 1920s, while developing methods for measuring small amounts of alcohol, Erik M. P. Widmark noticed that a dose of alcohol always produced a higher blood level than dilution through the whole body weight would predict, because bones and fat hold little water. He added an empirical factor, r, to correct for this (Searle, 2015). His formula, published in 1932 and shown as Equation 4.2, was still described in 2015 as the most popular method for blood alcohol calculations (Searle, 2015).
The Widmark factor (r, in litres per kilogram) reflects body water and depends on sex and body mass index; Searle (2015) tabulates about 0.72 for a man with a body mass index of 24.7, and 0.61 or 0.65 for a woman with a body mass index of 22.8, depending on which of two published tables is used; Searle concluded that the lower value, from Forrest’s table, appears to be in error. The elimination rate, β, averages about 15 milligrams per 100 millilitres per hour (Jones, 2010), and A is the number of standard drinks multiplied by 13.45 grams. Worked example 4.2 puts these together.
Worked example 4.2 (hypothetical). A woman weighing 60 kg, with r = 0.65, drinks three standard drinks (40.35 g of alcohol). If all of it were absorbed at once, her BAC would be 100 × 40.35 ÷ (0.65 × 60) = 103.5 mg per 100 mL; two hours after she started drinking, with β = 15, the estimate is 103.5 − 30 = 73.5. A man weighing 80 kg, with r = 0.72, who drinks the same three drinks over the same time has an estimated 70.1 − 30 = 40.1. The same drinks give one person nearly twice the blood level of the other. Calculator 4.2 lets you change each input and watch the effect.
The box below explains why every estimate of this kind must be treated with caution.
Why any BAC estimate is uncertain
The Widmark formula assumes that all the alcohol has been absorbed, that elimination ran at a constant rate from the first drink, and that the person’s r and β are known. None of these is exact. Searle (2015) shows that uncertainty in these inputs, and in the volume and strength of the drinks, combines into a range around the central estimate, and Jones (2010) found elimination rates from 10 to 35 milligrams per 100 millilitres per hour. The calculator therefore teaches the formula and cannot tell anyone whether they are impaired or fit to drive; measurable effects begin well below the legal limit (Table 4.2).
Using Equation 4.2, estimate the BAC of a hypothetical person weighing 70 kg (r = 0.68) three hours after starting to drink four standard drinks, with β = 15, and then check your answer in Calculator 4.2. (You should find about 113 mg per 100 mL before elimination and about 68 after three hours.) Then change only β to 25 and explain why a single average rate can mislead.
Public health agencies must also communicate risk to people who will never use a formula, the subject of the final part of this section.
4.1 Canada’s Guidance on Alcohol and Health as Risk Communication
In January 2023, the Canadian Centre on Substance Use and Addiction (CCSA) published Canada’s Guidance on Alcohol and Health, which replaced the Low-Risk Alcohol Drinking Guidelines of 2011 (CCSA, 2023; Paradis et al., 2023). It serves here as an example of risk communication, the work of turning scientific estimates of harm into information that people can use; HSCI 402 examines the evidence on alcohol harms behind it.
4.1.1 Choosing an Acceptable Level of Risk
Any drinking guideline must decide how much risk counts as low. The expert panel noted that advice about voluntary activities generally uses a lifetime risk of premature death of 1 in 1,000, while many countries have based alcohol guidelines on a higher risk of 1 in 100. Its modelling found that, in Canada, the 1 in 1,000 limit corresponded to two standard drinks per week and the 1 in 100 limit to six (Paradis et al., 2023). The box below shows the continuum of risk that resulted.
The continuum of risk in Canada’s Guidance on Alcohol and Health (2023)
- Zero standard drinks per week: not drinking has benefits, such as better health and better sleep.
- One to two per week: low risk; a person is likely to avoid alcohol-related consequences for themselves or others.
- Three to six per week: moderate risk; the risk of several cancers, including breast and colon cancer, increases.
- Seven or more per week: increasingly high risk; the risk of heart disease or stroke increases significantly, and each additional drink adds risk.
- Per occasion: more than two standard drinks is associated with an increased risk of harms to self and others, including injuries and violence.
- Pregnancy: when pregnant or trying to become pregnant, there is no known safe amount of alcohol.
4.1.2 Features of the Guidance as Communication
Table 4.3 sets out four design choices in the guidance and the principle of risk communication behind each.
Table 4.3. Risk communication choices in Canada’s Guidance on Alcohol and Health (CCSA, 2023; Paradis et al., 2023).
| Choice | What the guidance does | Principle |
|---|---|---|
| A continuum | Presents risk as rising with each drink: less alcohol is better wherever a person starts. | Avoids implying that drinking below one threshold is safe. |
| A stated risk level | Bases its categories on lifetime risks of 1 in 1,000 and 1 in 100. | Makes the value judgement behind the numbers visible. |
| A common unit | Expresses all advice in Canadian standard drinks. | Gives people a unit they can count. |
| Labelling | Suggests that standard-drink labels on containers could be a particularly effective change. | Puts the information where the decision is made. |
The guidance is advice, and its influence depends on whether people know it, understand standard drinks and trust the message. It also states that people should not start or increase drinking for health benefits (Paradis et al., 2023). Lesson 12 returns to alcohol regulation.
A hypothetical person reports two 473 mL tall cans of 5% beer on Friday and a 266 mL (9 oz) glass of 14% wine on Saturday and again on Sunday. Use Calculator 4.1 to convert each container, add the results, place the weekly total on the continuum of risk shown above, and check whether any occasion exceeded two standard drinks. (Each can holds 1.39 drinks and each glass about 2.18, for about 7.1 in the week.)
Summary and Transition
Alcohol depresses the central nervous system by enhancing GABA-A inhibition and blocking NMDA excitation. It is absorbed fastest from the small intestine, dissolves in body water and is removed at a roughly constant amount per hour, so its blood level is predictable in principle with the Widmark formula and uncertain in practice. The standard drink provides a common unit of dose, which Canada’s 2023 guidance uses to communicate risk. Section 2 turns to the prescription sedatives that act on the same GABA-A receptor.
Key Takeaways
- 1.1 Alcohol is a central nervous system depressant: at intoxicating concentrations it enhances GABA-A receptor function and inhibits NMDA glutamate receptors, so inhibition rises and excitation falls. It is a relatively nonspecific drug with many other targets, and with long-term heavy drinking the brain adapts in ways that produce tolerance and a withdrawal state of too little inhibition.
- 2.1 Alcohol is absorbed fastest from the small intestine, so food slows its rise; it dissolves in body water, so people with less body water reach higher levels; and the liver breaks it down through ADH and ALDH. Because ADH is saturated, elimination is zero-order, about 15 mg per 100 mL per hour on average, and food, body water, medicines and liver disease all change the blood level produced by the same drink.
- 3.1 A Canadian standard drink contains 17.05 mL or 13.45 g of pure alcohol, and the number in a container equals its volume times its ABV divided by 100, divided by 17.05. Container size and strength can make one serving equal to two or more standard drinks.
- 3.2 The Widmark formula estimates blood alcohol from dose, body weight, a body-water factor and the elimination rate, and it shows why the same drinks give different people very different levels. Every estimate carries wide uncertainty because the formula assumes complete absorption, a constant elimination rate and known values of r and β, so no calculator can show whether a person is fit to drive.
- 4.1 Canada’s Guidance on Alcohol and Health (2023) communicates risk on a continuum, from low risk at one to two standard drinks per week to increasingly high risk at seven or more, based on explicit lifetime risk thresholds of 1 in 1,000 and 1 in 100. It uses the standard drink as a common unit, and its expert panel proposed standard-drink labelling to put information where decisions are made.
Reflection
Two hypothetical friends each drink three Canadian standard drinks (40.35 g of alcohol) over the same evening. One weighs 60 kg and has a Widmark factor of 0.65; the other weighs 80 kg and has a Widmark factor of 0.72. Two hours after they start, the Widmark formula (with an elimination rate of 15 mg per 100 mL per hour) estimates about 74 mg per 100 mL for the first and about 40 mg per 100 mL for the second. Using what you learned about absorption, distribution and elimination, explain why their blood alcohol levels differ, give two reasons why either estimate could be wrong, and say what the example suggests about the usefulness of counting standard drinks.
The two friends drank the same 40.35 g of alcohol, but alcohol dissolves in body water and poorly in fat, so the dose is diluted into different volumes. The lighter friend has less body weight and a lower Widmark factor, which reflects a smaller share of body water, so the same alcohol produces a higher concentration (103.5 mg per 100 mL before elimination, against 70.1). The liver removes roughly the same amount per hour in both, about 15 mg per 100 mL, because alcohol dehydrogenase is saturated, so the gap persists for hours.
Either estimate could be wrong for several reasons. The formula assumes that all the alcohol has been absorbed, yet a meal slows stomach emptying and delays the peak. It also assumes a fixed elimination rate, while Jones (2010) found rates from 10 to 35 mg per 100 mL per hour, and the Widmark factor itself varies with body mass index. The poured drinks may also have been larger than reference servings.
Counting standard drinks is still useful because it gives a common unit for dose and lets people compare containers. It cannot predict an individual’s blood level precisely, which is why the 2023 guidance frames risk as a continuum and why no calculator can tell a person that driving is safe.
Minimum 20 characters required.
Question 1: Which pair of actions best describes how alcohol depresses the central nervous system?
Question 2: Blood alcohol usually falls by about the same amount each hour, whatever the starting level. What explains this pattern?
Question 3: How many Canadian standard drinks are in a 750 mL bottle of wine at 12% alcohol?
Question 4: Which statement matches the continuum of risk in Canada’s Guidance on Alcohol and Health (2023)?
Benzodiazepines, Z-Drugs, Barbiturates and GHB
Content note
This section mentions overdose deaths and withdrawal seizures. If you would like support, the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677) and the Hope for Wellness Help Line for Indigenous people (1-855-242-3310) are available at any time.
Introduction
Section 1 showed that alcohol quiets the brain partly by enhancing the GABA-A receptor. A large family of medicines does the same thing more selectively. They are often called sedative-hypnotics: sedatives calm, and hypnotics (from the Greek word for sleep) help people fall asleep. The family includes the benzodiazepines, the related Z-drugs and the older barbiturates. Together with alcohol they are joined in this section by gamma-hydroxybutyrate (GHB), a depressant that acts through a different GABA receptor.
These drugs are common in Canada. In 2016, 12.9% of adults aged 65 and older covered by the public drug programs that report to the Canadian Institute for Health Information (CIHI) used a benzodiazepine, and 6.1% used one chronically; use was higher among women (15.9%) than men (9.3%) and rose with age, from 11.1% at ages 65 to 74 to 16.9% at 85 and older (CIHI, 2018). Among junior high and high school students in the 2023–24 Canadian Student Alcohol and Drugs Survey, 2% had used sedatives for non-recommended purposes in the previous year (Health Canada, 2025b).
Learning Objectives
- 5.1 Explain how benzodiazepines, Z-drugs and barbiturates act at different sites on the GABA-A receptor, and why barbiturates have a narrower margin of safety.
- 5.2 Describe the medical uses, half-lives and legal status in Canada of the main benzodiazepines and Z-drugs, and explain how half-life and tolerance shape the effects of repeated doses.
- 5.3 Describe the history, uses and legal status in Canada of barbiturates, and explain why benzodiazepines largely replaced them.
- 5.4 Describe GHB, its medical form sodium oxybate, its steep dose-response relationship and its legal status in Canada, and compare it with the other depressants in Sections 1 and 2.
- 6.1 Explain how physical dependence develops with prescribed use and why abrupt withdrawal from depressants can be dangerous.
- 6.2 Summarize the evidence for deprescribing benzodiazepines in older adults, including the EMPOWER trial, and calculate a number needed to treat from its results.
5.1 A Shared Target: The GABA-A Receptor
The GABA-A receptor is a channel made of five protein subunits around a central pore. When GABA binds, the pore opens and chloride ions flow into the nerve cell, making it less likely to fire. As Lesson 3 explained, a drug can bind to another part of a receptor and change its response to the natural messenger, and several depressants do this at different sites, as Figure 4.3 shows.
3-D Model 4.2 shows the same binding sites on the atomic structure of a human GABA-A receptor, with GABA, the benzodiazepine diazepam and the barbiturate phenobarbital in place, and adds flumazenil, a medicine that blocks the benzodiazepine site and is used to reverse benzodiazepine overdose.
The binding site matters for safety. Benzodiazepines bind to their own site on the GABA-A receptor and boost the effect of GABA, so that more chloride enters the cell when GABA is present (Ashton, 2002; Griffin et al., 2013). Barbiturates act differently: they prolong and strengthen GABA’s action and, at higher concentrations, open the receptor channel directly (Löscher & Rogawski, 2012). A drug that can open the channel by itself has no natural ceiling set by the amount of GABA available, which helps explain why barbiturates have a low therapeutic index (the ratio between toxic and effective doses introduced in Lesson 3) and why benzodiazepines largely replaced them (Griffin et al., 2013). The wider safety margin of benzodiazepines applies to a benzodiazepine taken alone; Section 4 explains how combinations erase much of it. 3-D Model 4.3 lets you compare these actions at a synapse: when the release of GABA is switched off, a benzodiazepine has nothing to boost, while a barbiturate at higher concentrations still opens the channel, and later steps add alcohol and a combination of depressants.
Different versions of the GABA-A receptor are built from different subunits, and they are linked to different effects: receptors containing the alpha 1 subunit to sedation, alpha 2 to relief of anxiety, and alpha 1, alpha 2 and alpha 5 to anticonvulsant effects (Ashton, 2002). This helps explain why one drug is marketed as a sleeping pill and a close relative as an anti-anxiety medicine.
5.2 Benzodiazepines and Z-Drugs
The first benzodiazepine, chlordiazepoxide, was marketed in 1960 (López-Muñoz et al., 2005). Benzodiazepines are now used for anxiety, insomnia, muscle spasm and epilepsy, before and during surgery for their calming and memory-blocking effects, for panic disorder, and in the management of alcohol withdrawal (Griffin et al., 2013). The Z-drugs, zopiclone and zolpidem, have different chemical structures but the same effects on the body and the same mechanism of action, and they are prescribed mainly for sleep (Ashton, 2002).
5.2.1 Half-Life Sets How Long a Drug Lasts
The members of the family differ most in how long they stay in the body. Table 4.4 lists half-lives from the manual written by Professor C. Heather Ashton (2002); some drugs, such as diazepam, are converted into active metabolites that last even longer.
Table 4.4. Elimination half-lives of selected benzodiazepines and Z-drugs (Ashton, 2002) and their status under the Controlled Drugs and Substances Act (CDSA) as of July 2026 (Justice Laws Website, 2026).
| Drug | Type | Half-life in hours [active metabolite] | Status in Canada |
|---|---|---|---|
| Triazolam | Benzodiazepine | 2 | CDSA Schedule IV |
| Oxazepam | Benzodiazepine | 4 to 15 | CDSA Schedule IV |
| Alprazolam | Benzodiazepine | 6 to 12 | CDSA Schedule IV |
| Temazepam | Benzodiazepine | 8 to 22 | CDSA Schedule IV |
| Lorazepam | Benzodiazepine | 10 to 20 | CDSA Schedule IV |
| Clonazepam | Benzodiazepine | 18 to 50 | CDSA Schedule IV |
| Diazepam | Benzodiazepine | 20 to 100 [36 to 200] | CDSA Schedule IV |
| Zolpidem | Z-drug | 2 | CDSA Schedule IV |
| Zopiclone | Z-drug | 5 to 6 | Prescription drug; not listed in the CDSA schedules |
As of July 2026, Schedule IV of the CDSA lists “benzodiazepines, their salts and derivatives” as a group, so new benzodiazepine-type chemicals fall under it unless they are listed elsewhere; one exception, flunitrazepam, is listed in Schedule I (Justice Laws Website, 2026). Lesson 5 shows how unregulated benzodiazepine-type drugs such as bromazolam have entered the toxic drug supply, and Lesson 11 explains how the drug schedules work.
5.2.2 Half-Life with Repeated Doses
Half-life also determines what happens when a drug is taken every day. Each dose adds to whatever remains from earlier doses, so the level in the body builds up until the amount removed between doses equals the amount taken in, a balance called steady state (Lesson 3). The amount of build-up depends on how much of each dose is still present when the next one is taken, which Equation 4.3 expresses as an accumulation factor. Worked example 4.3 applies it to diazepam.
Worked example 4.3. Klotz and colleagues (1975) gave diazepam to 33 healthy volunteers aged 15 to 82 and found that its half-life increased with age, from about 20 hours at age 20 to about 90 hours at age 80. With one dose every 24 hours, a 20-hour half-life gives R = 1 ÷ (1 − 0.524 ÷ 20) = 1.77, and steady state is approached after about 80 hours (3.3 days). A 90-hour half-life gives R = 1 ÷ (1 − 0.524 ÷ 90) = 5.93, and steady state is approached only after about 360 hours (15 days). After a dose change, effects keep shifting for about two weeks in the older person and about three days in the younger one. Use Calculator 4.3 to compare other drugs from Table 4.4.
Klotz and colleagues also found that diazepam clearance did not change with age; the longer half-life came from a larger volume of distribution, so the average steady-state level from the same dose was similar at different ages (Klotz et al., 1975). The differences that matter for older adults are timing and sensitivity: the drug builds up and leaves more slowly, and older people show more confusion, disorientation, falls and fractures at a given dose (Griffin et al., 2013). The American Geriatrics Society’s 2023 Beers Criteria likewise state that older adults are more sensitive to benzodiazepines, which raise their risk of cognitive impairment, delirium, falls and fractures (American Geriatrics Society, 2023).
5.2.3 Tolerance with Regular Use
Ashton (2002) reported that tolerance to the sleep-promoting effect develops rapidly, so that sleep returns to its pre-treatment pattern after a few weeks of regular use, while tolerance to the anti-anxiety effect develops more slowly, with little evidence of benefit beyond a few months. This helps explain how people come to take a sleeping pill for years after its benefit has faded.
5.3 Barbiturates
Barbiturates dominated sedative prescribing for half a century before benzodiazepines arrived. Figure 4.4 places them on a timeline with the other drugs in this section.
Joseph von Mering and Emil Fischer described the sedative properties of barbital in 1903, and the same group synthesized phenobarbital in 1911 (López-Muñoz et al., 2005). Barbiturates were most widely used in the 1930s and 1940s as sedatives and sleeping medicines, and phenobarbital became an important treatment for epilepsy. No barbiturate overcame their two main drawbacks, dependence and death by overdose, which followed from their small therapeutic margin, and after chlordiazepoxide appeared in 1960 their use declined except in anesthesia and certain kinds of seizure (López-Muñoz et al., 2005). In Canada, as of July 2026, barbiturates are listed in Schedule IV of the CDSA (Justice Laws Website, 2026).
5.4 GHB
Gamma-hydroxybutyrate (GHB) occurs naturally in small amounts in the brain, but as a drug it acts mainly on the GABA-B receptor, a different receptor from the GABA-A target of alcohol, benzodiazepines and barbiturates (Busardò & Jones, 2015). It has both medical and non-medical uses, which the box and the accordion below summarize.
Sodium oxybate, the medical form of GHB
The sodium salt of GHB, sodium oxybate (brand name Xyrem), is a treatment for cataplexy, the sudden loss of muscle tone triggered by emotions such as laughter in people with narcolepsy (Busardò & Jones, 2015). Health Canada issued its Notice of Compliance for Xyrem for cataplexy in patients with narcolepsy on 5 August 2005, and its 2006 summary of the decision states that, because of the risk of misuse, Xyrem is distributed only through a restricted program with a single wholesaler (Health Canada, 2006). Busardò and Jones reported in 2015 that in some European countries sodium oxybate was also used to manage alcohol withdrawal (Busardò & Jones, 2015). As of July 2026, GHB itself is listed in Schedule I of the CDSA, the schedule that also lists opioids such as heroin and fentanyl (Justice Laws Website, 2026).
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2008) described GHB as having a steep dose-response curve: a small increase in dose can cause serious toxic effects, including impaired consciousness and coma. Busardò and Jones (2015) reported that a fatal dose may be only five to eight times a recreational dose, a very narrow margin compared with most medicines.
Effects begin 15 to 30 minutes after a dose and last between one and six hours. Most studies find a plasma half-life of 30 to 50 minutes, so GHB disappears from the blood within hours (Busardò & Jones, 2015). This short half-life means that people who take GHB regularly may dose every few hours, around the clock.
Long-term frequent use leads to tolerance and physical dependence, and abrupt cessation can produce a withdrawal syndrome with anxiety, insomnia, tremor, a rapid heart rate, confusion, delirium and hallucinations; seizures may be life-threatening, as they sometimes are in alcohol withdrawal, and medical treatment in hospital is needed (Busardò & Jones, 2015).
GHB combines a legitimate medical use, a narrow margin of safety and a dangerous withdrawal syndrome. With GHB in place, Table 4.5 brings together the depressants covered in Sections 1 and 2.
Table 4.5. The depressants in Sections 1 and 2 compared (sources as cited in the text; legal status as of July 2026).
| Class | Main action | Medical use | Status in Canada | Notable risks |
|---|---|---|---|---|
| Alcohol | Enhances GABA-A, inhibits NMDA and other targets | Not prescribed as a sedative | Legal for adults; sale controlled by provinces and territories | Poisoning; dangerous withdrawal after heavy use |
| Benzodiazepines | Boost GABA at the GABA-A receptor | Anxiety, insomnia, seizures, alcohol withdrawal | CDSA Schedule IV | Falls and sedation in older adults; dependence |
| Z-drugs | Benzodiazepine site of GABA-A | Insomnia | Zolpidem Schedule IV; zopiclone prescription only | Similar to benzodiazepines |
| Barbiturates | Prolong GABA-A opening; open it directly at high doses | Epilepsy (phenobarbital), anesthesia | CDSA Schedule IV | Low therapeutic index; overdose |
| GHB | Mainly GABA-B | Cataplexy in narcolepsy (sodium oxybate) | CDSA Schedule I; sodium oxybate authorized in 2005 with restricted distribution | Steep dose-response; severe withdrawal |
The next part looks at withdrawal across the whole class.
6.1 Dependence with Prescribed Use and the Dangers of Abrupt Withdrawal
A person who takes a benzodiazepine every day as prescribed can become physically dependent on it without ever misusing it. Physical dependence means that the body has adapted to the drug, so that stopping it produces withdrawal symptoms. It is distinct from addiction, which involves compulsive use despite harm (Lesson 8). The adaptation mirrors the one described for alcohol in Section 1.
Abrupt withdrawal is especially dangerous. Ashton (2002) explained that sudden withdrawal from benzodiazepines leaves the brain in a state of GABA underactivity, and that abrupt or over-rapid withdrawal, especially from high doses, can cause severe symptoms including convulsions, psychotic reactions and acute anxiety states. The same danger applies across the depressants: alcohol withdrawal can bring seizures (Valenzuela, 1997), and GHB withdrawal can bring delirium and seizures (Busardò & Jones, 2015). For this reason the College of Physicians and Surgeons of British Columbia’s practice standard on opioids and sedatives states that benzodiazepines must not be abruptly discontinued and must be tapered slowly (CPSBC, 2026). Withdrawal management itself is developed in HSCI 402, and the box below summarizes the principles of tapering that Ashton set out.
Tapering in the Ashton Manual
Ashton’s manual, Benzodiazepines: How They Work and How to Withdraw (revised 2002), set out principles of slow, patient-paced tapering. Anyone withdrawing from long-term benzodiazepines should reduce the dose slowly, usually over some months; switching to a long-acting, slowly eliminated benzodiazepine such as diazepam can smooth the process; and the person withdrawing should have control over the pace. Ashton regarded the classic six-week withdrawal as much too fast for many long-term users (Ashton, 2002). A 2025 joint guideline convened by the American Society of Addiction Medicine also advises a gradual taper planned with the patient, which may take months or even years; its authors found limited evidence comparing tapering schedules, so its advice on pace rests mainly on clinical consensus (Brunner et al., 2025). These are principles for people working with a prescriber, and the schedule in any individual case is a clinical decision.
6.2 Deprescribing in Older Adults
Deprescribing is the planned, supervised reduction or stopping of a medicine whose harms may now outweigh its benefits. Benzodiazepines are a common target in older adults because the harms accumulate with age. A Canadian deprescribing algorithm lists physical dependence, falls, memory disorders, dementia, functional impairment, daytime sedation and motor vehicle crashes as harms of benzodiazepines and Z-drugs, with risks that increase in older people (Deprescribing.org, 2019).
In 2018, a Canadian team led by Kevin Pottie published an evidence-based guideline on deprescribing benzodiazepine receptor agonists, the term for benzodiazepines and Z-drugs together. It recommends that slow tapering be offered to adults aged 65 and older who take these drugs for insomnia, regardless of how long they have taken them, and suggests offering it to adults aged 18 to 64 who have used them for more than four weeks (Pottie et al., 2018). The accompanying algorithm gives an example of tapering by about 25% every two weeks in collaboration with the patient, with smaller 12.5% steps near the end, and notes that withdrawal symptoms such as insomnia, anxiety and irritability are usually mild and last from days to a few weeks (Deprescribing.org, 2019). There are signs that practice was already changing before the guideline appeared: among seniors in the provinces with data for the whole period, benzodiazepine use fell from 17.5% in 2011 to 14.0% in 2016 (CIHI, 2018). Case 4.1 describes a Canadian trial that tested one way of starting the deprescribing conversation.
Cara Tannenbaum and colleagues (2014) recruited 303 long-term benzodiazepine users aged 65 to 95 from 30 community pharmacies in Quebec. Fifteen pharmacies were randomly allocated to the intervention, in which participants received printed educational material describing the risks of benzodiazepines and a stepwise tapering protocol; the other fifteen continued usual care. After six months, 62% of those who received the material had raised stopping with a physician or pharmacist. Benzodiazepine use had been discontinued by 27% of the intervention group compared with 5% of the control group, a risk difference of 23 percentage points (95% confidence interval 14 to 32), and a further 11% had reduced their dose. Age, sex, duration of use and dose did not change the effect (Tannenbaum et al., 2014).
EMPOWER was a cluster randomized trial, in which whole groups (here pharmacies) are randomly allocated, so that participants who share a pharmacy all receive the same condition. Its result is often expressed as a number needed to treat (NNT), the number of people who must receive an intervention for one additional person to benefit, calculated as 1 divided by the risk difference.
EMPOWER is one trial, in one province, with six months of follow-up. Two systematic reviews published in 2025 found that educating patients may increase the proportion who stop these drugs, but one rated the evidence as low in certainty and the other found most studies at high risk of bias and wide variation between them, so evidence on how best to support deprescribing is still evolving (Zeraatkar et al., 2025; McEvoy et al., 2025).
Using the EMPOWER results in Case 4.1, calculate the risk difference for discontinuation (27% minus 5%) and the NNT. Compare it with the NNT of 4 that the authors reported from their risk difference of 23 points, and explain in two sentences why an NNT of about 4 is a large effect for patient education. (1 ÷ 0.22 = 4.5; 1 ÷ 0.23 = 4.3, reported as 4.)
The flip cards below review four terms from this section.
Summary and Transition
Benzodiazepines, Z-drugs and barbiturates all work through the GABA-A receptor, but barbiturates can open the channel directly, which gives them a narrower margin of safety. Half-life determines how long a drug lasts and how slowly it builds up and clears, a difference that matters in older adults. Regular use, even as prescribed, produces tolerance and physical dependence, so depressants are stopped by slow tapering, and the 2014 EMPOWER trial is one example in which patient education helped older adults stop, although 2025 reviews rated the wider evidence as uncertain. GHB acts through GABA-B and has a narrow margin outside medicine. Section 3 turns to depressants that come from household and industrial products: the inhalants.
Key Takeaways
- 5.1 Benzodiazepines and Z-drugs bind to their own site on the GABA-A receptor and boost GABA’s effect, so their action is limited by the GABA available. Barbiturates prolong the channel’s opening and, at high concentrations, open it directly, which gives them a low therapeutic index; the wider margin of benzodiazepines applies only when they are taken alone.
- 5.2 Benzodiazepines treat anxiety, insomnia, seizures, muscle spasm and alcohol withdrawal, and Z-drugs are used mainly for sleep; as of July 2026, most are in Schedule IV of the CDSA, while zopiclone is a prescription drug outside the schedules. Half-lives range from about 2 hours to several days, so long-acting drugs such as diazepam build up for days, especially in older adults, and tolerance to the sleep effect develops within weeks.
- 5.3 Barbiturates were the main sedatives from the early twentieth century until the 1960s, and phenobarbital became an important treatment for epilepsy. Dependence and death by overdose, which follow from their small therapeutic margin, led benzodiazepines to replace them; in Canada, as of July 2026, they are listed in Schedule IV of the CDSA.
- 5.4 GHB acts mainly through GABA-B receptors, has a steep dose-response curve, a short half-life and a severe withdrawal syndrome, and, as of July 2026, is in Schedule I of the CDSA, while its medical form, sodium oxybate, treats cataplexy under a restricted program. Compared side by side, the depressants of Sections 1 and 2 differ in receptor, medical use, legal status and risk.
- 6.1 Regular use, even exactly as prescribed, produces physical dependence, which differs from addiction. Abrupt withdrawal leaves the brain with too little GABA activity and can cause convulsions, so benzodiazepines must be tapered slowly, as Ashton’s manual and British Columbia’s practice standard require.
- 6.2 Canada’s 2018 guideline recommends offering slow tapering to adults aged 65 and older who take benzodiazepine receptor agonists for insomnia. In the EMPOWER trial, patient education led 27% of older users to stop compared with 5% under usual care, a number needed to treat of about 4.
Reflection
A hypothetical 78-year-old has taken a benzodiazepine for sleep every night for six years and asks a pharmacist whether to keep taking it. Drawing on Section 2, explain (a) why the benefit for sleep may have faded, (b) two harms that are more likely at this age, (c) why stopping suddenly would be unwise, and (d) what the EMPOWER trial, in which 27% of the intervention group and 5% of the control group had stopped benzodiazepines after six months, suggests about how such a conversation might begin.
(a) Ashton (2002) reported that tolerance to the sleep-promoting effect of benzodiazepines develops within a few weeks of regular use, after which sleep returns to its pre-treatment pattern. After six years, the pill may be preventing withdrawal symptoms more than it is treating insomnia.
(b) Older adults are more sensitive to these drugs. Griffin and colleagues (2013) describe greater confusion and disorientation and a higher risk of falls and fractures, the American Geriatrics Society’s 2023 Beers Criteria add cognitive impairment and delirium (American Geriatrics Society, 2023), and the Canadian deprescribing algorithm adds memory problems, daytime sedation and motor vehicle crashes. For a long-acting drug such as diazepam, Klotz and colleagues (1975) found a half-life of about 90 hours at age 80, so effects linger for days.
(c) Six years of use will have produced physical dependence. Stopping suddenly leaves the brain with too little GABA activity, which can cause severe anxiety, insomnia and, after high doses, convulsions, so any reduction should be a slow taper planned with the prescriber, as the 2018 Canadian guideline recommends.
(d) In the EMPOWER trial (Tannenbaum et al., 2014), giving patients clear written information about risks and a stepwise taper led 62% to raise the topic with a clinician and produced a 22 to 23 point increase in discontinuation, an NNT of about 4. That was one trial, and two 2025 systematic reviews found that patient education may help while rating the wider evidence as uncertain (Zeraatkar et al., 2025; McEvoy et al., 2025). The conversation can begin with information the patient owns, followed by shared decisions about a gradual plan.
Minimum 20 characters required.
Question 1: Why do barbiturates have a narrower margin of safety than benzodiazepines?
Question 2: Klotz and colleagues (1975) found that diazepam’s half-life rose from about 20 hours at age 20 to about 90 hours at age 80. With one dose a day, what is the main practical consequence for an older person?
Question 3: Which statement about GHB is accurate?
Question 4: In the EMPOWER trial, 27% of the intervention group and 5% of the control group had stopped benzodiazepines after six months. What is the number needed to treat calculated from these percentages?
Inhalants, Volatile Solvents and Nitrous Oxide
Content note
This section discusses sudden deaths linked to inhalants. If you would like support, the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677) and the Hope for Wellness Help Line for Indigenous people (1-855-242-3310) are available at any time.
Introduction
Most of the drugs in this course are manufactured to act on the body, whether as medicines or for an illegal market. Inhalants are different: they are breathable chemical vapours from products made for other purposes, such as glue, gasoline, spray paint, lighter fuel and whipped-cream chargers, that produce mind-altering effects when they are inhaled. Because they are cheap, legal and found in most homes and shops, they are easy for young people to obtain; glue, shoe polish, spray paint, gasoline and lighter fluid were among the inhalants most commonly used by young people in the United States in the national survey reports cited by Howard and colleagues (2011), who also note that the hundreds of products that can be inhaled make the class difficult to classify.
This section sorts inhalants into groups, explains how most of them act as depressants, describes the acute dangers that can follow even a single use and the damage that can follow repeated use, and then examines nitrous oxide, whose recreational use and harms a European agency described as growing in 2022 and which drew a Health Canada advisory in 2025.
Learning Objectives
- 7.1 Classify inhalants into volatile solvents, aerosols, gases and nitrites, give examples of each, and describe their legal position in Canada.
- 7.2 Explain how volatile solvents act as central nervous system depressants and why their effects resemble alcohol intoxication.
- 7.3 Describe the acute risks of inhalant use, including sudden sniffing death, asphyxiation and injury.
- 7.4 Describe the long-term harms of repeated solvent use, and explain why early inhalant use may mark rather than cause later drug problems.
- 7.5 Explain how heavy nitrous oxide use inactivates vitamin B12 and damages the spinal cord and nerves, and interpret the limits of case-report evidence.
- 7.6 Describe the trends in nitrous oxide use reported in Europe in 2022 and Health Canada’s 2025 response, and interpret the limits of poison centre data.
7.1 What Counts as an Inhalant
The United States National Institute on Drug Abuse (NIDA) groups inhalants into four categories according to the form of the product, as Table 4.6 shows. The categories are practical: the same chemical can appear in more than one product type, and the products in a group do not all act in the same way on the body.
Table 4.6. The four categories of inhalants, with examples and main actions (NIDA, n.d.-a; NIDA, n.d.-b; Jevtović-Todorović et al., 1998).
| Category | Examples | Main action |
|---|---|---|
| Volatile solvents (liquids that turn to vapour at room temperature) | Paint thinners, dry-cleaning fluids, gasoline, glues, correction fluids, felt-tip markers | Central nervous system depressant |
| Aerosols (sprays containing propellants and solvents) | Spray paint, deodorant, hair spray, cooking oil spray, fabric protector | Central nervous system depressant |
| Gases | Medical anesthetics (ether, chloroform, halothane, nitrous oxide); household and commercial gases (butane, propane, refrigerants) | Depressant; nitrous oxide acts mainly by blocking NMDA receptors |
| Nitrites | Amyl, isobutyl and cyclohexyl nitrite | Widen blood vessels and relax muscles; mainly used to enhance sex |
The nitrites stand apart. Unlike the other three groups, they act mainly by dilating blood vessels and relaxing muscles, and they are used mainly as sexual enhancers (NIDA, n.d.-a). The remaining groups all slow the central nervous system, and they are the focus of the rest of this section.
The legal position of inhalants in Canada reflects their ordinary uses. Solvents, aerosols and gases are lawful consumer and industrial products. As of July 2026, none of the inhalants in Table 4.6 is listed as a controlled psychoactive substance in Schedules I to V of the Controlled Drugs and Substances Act; several solvents found in such products, including toluene, acetone and methyl ethyl ketone, and the anesthetic ethyl ether appear in Schedule VI as Class B precursor chemicals because they can be used in making other drugs (Justice Laws Website, 2026). Nitrous oxide is a special case: Health Canada regulates nitrous oxide sold for inhalation as a drug that only an authorized health care professional may administer, and it states that advertising and selling nitrous oxide products for inhalation to the public is prohibited (Health Canada, 2025c). Use Interactive 4.1 to practise sorting common products into the four categories.
Sort the products into inhalant categories
Choose a category for each product, then select Check. Each answer comes with a note on the main concern, drawn from the sources in this section.
7.2 How Volatile Solvents Act on the Brain
Animal studies suggest that many common volatile solvents and anesthetic gases behave like other central nervous system depressants, a class that includes alcohol, sedatives and anesthetics, with similar effects on behaviour and similar mechanisms of action (NIDA, n.d.-c). Like alcohol, solvents act on both sides of the brain’s balance between inhibition and excitation.
7.2.1 GABA, Glutamate and Dopamine
Reviewing the laboratory evidence, Howard and colleagues (2011) quote the conclusion of Bowen and colleagues that solvents, like other depressants, act as positive modulators of GABA-A receptors, which is the same kind of action that Section 2 described for benzodiazepines. Toluene, a solvent found in model glue, spray paint and paint remover, also produces many of its depressant effects by blocking glutamate’s action at NMDA receptors, and benzene, xylene and several other solvents block NMDA receptors as well (Howard et al., 2011). In rats, toluene increases dopamine levels in the brain’s reward pathways in a way that resembles other drugs that people use repeatedly, which may help explain its rewarding effects (Howard et al., 2011). A 2025 review of toluene by Shaw and colleagues described similar laboratory findings at GABA-A and NMDA receptors and in dopamine systems (Shaw et al., 2025), so these mechanisms rest mainly on laboratory and animal studies.
7.2.2 An Intoxication that Resembles Alcohol
Because they act on the same receptors, inhalants produce a state similar to alcohol intoxication: dizziness, poor coordination, slurred speech, euphoria, lethargy, slowed reflexes, slowed thinking and movement, tremor, blurred vision, muscle weakness and, at higher exposures, stupor or coma (Howard et al., 2011). Toluene and trichloroethylene produce motor excitement at low concentrations and sedation, anesthesia, coma and death at higher ones (Howard et al., 2011). In studies of nonhuman primates, labelled toluene, butane and acetone were rapidly taken up into the brain and rapidly cleared (Howard et al., 2011). Rapid entry and exit help explain why the intoxication is brief, and why repeated inhalations within a short period produce the high concentrations behind several of the acute dangers in the next part.
7.3 Acute Risks
The most frightening feature of inhalants is that serious harm can occur during a single episode of use. The accordion below describes the main acute risks identified by NIDA and by Howard and colleagues (2011).
Highly concentrated chemicals can trigger a rapid, irregular heart rhythm (ventricular arrhythmia) and fatal heart failure within minutes of prolonged sniffing. This can happen in an otherwise healthy young person during a single session, and it is linked particularly to butane, propane and aerosol chemicals (NIDA, n.d.-b; Howard et al., 2011).
Repeated inhalations can create concentrations of fumes high enough to displace oxygen in the lungs (asphyxiation). Inhaling from a plastic bag over the head can block air from reaching the lungs altogether (suffocation) (NIDA, n.d.-b).
Several of these dangers arise from the chemistry of the product and the setting of use, independently of the brain’s reward system, a theme that Lesson 3 introduced as drug, set and setting. The damage that follows repeated use is different, accumulating slowly in the nervous system and other organs.
7.4 Long-Term Harms of Solvents
Repeated inhalation of solvents can damage several organ systems, with the nervous system most affected. Imaging studies of people who use inhalants regularly, reviewed by Howard and colleagues in 2011, found thinning of the corpus callosum, the band of nerve fibres joining the two halves of the brain, and lesions in white matter, the tissue that carries signals between brain regions; recurrent intoxication can lead to impaired thinking from brain cell damage or loss, Parkinson-like movement problems and loss of coordination from damage to the cerebellum (Howard et al., 2011). Chronic toluene use damages the protective sheath around nerve fibres in a process that NIDA describes as clinically similar to multiple sclerosis, and it can cause hearing and vision loss (NIDA, n.d.-b). A 2025 review by Shaw and colleagues described white matter damage as the main pattern of brain injury after long-term toluene use, while noting that information on how toluene causes this damage is still scarce (Shaw et al., 2025). The flip cards summarize the main organ systems involved.
Howard and colleagues (2011) also caution against reading too much into the link between early inhalant use and later problems. They cite a 2005 United States estimate that young people who used inhalants by ages 12 or 13 were nearly five times as likely as their peers to have used another drug, but some researchers argue that early inhalant use marks a group of young people already facing many difficulties, and that it may not cause later drug use. Lesson 10 develops the risk and protective factors behind such patterns. The next part turns to nitrous oxide, whose harms drew warnings from European and Canadian agencies in 2022 and 2025.
7.5 Nitrous Oxide
Nitrous oxide, sometimes called laughing gas, is used in medicine and dentistry. Health Canada describes nitrous oxide for inhalation as a drug to be administered only by authorized health care professionals, for uses such as sedation and pain relief during medical and dental procedures (Health Canada, 2025c). The same gas is used in industry and as the propellant in whipped-cream chargers.
7.5.1 How It Acts
Nitrous oxide works differently from the solvents. At concentrations used in anesthesia, it blocks NMDA glutamate receptors (Jevtović-Todorović et al., 1998), which places it pharmacologically close to the dissociative anesthetics such as ketamine that Lesson 7 covers. Its acute risks include loss of consciousness and, when the gas displaces air, asphyxia (Health Canada, 2025c); the very cold gas released from pressurized containers can cause frostbite, and larger high-pressure cylinders have been linked to lung injuries (EMCDDA, 2022).
7.5.2 Vitamin B12 and the Spinal Cord
The most distinctive harm comes from heavy or frequent use. Nitrous oxide oxidizes the cobalt atom at the centre of vitamin B12 and displaces the vitamin from methionine synthase, an enzyme that needs B12 to work (Oussalah et al., 2019). The vitamin is present in the body but cannot do its job, so a person can develop the effects of severe B12 deficiency even with a normal diet. Figure 4.5 traces the chain of events.
Oussalah and colleagues (2019) pooled individual data on 100 patients described in 85 publications on nitrous oxide toxicity. Their median age was 27 years and 57% had been exposed through recreational use. The most frequent diagnoses were subacute combined degeneration of the spinal cord (28%), myelopathy, meaning disease of the spinal cord (26%), and generalized demyelinating polyneuropathy, damage to the insulating sheath of the peripheral nerves (23%). Eighty percent had tingling or numbness in the limbs, 58% had an unsteady gait and 43% had weakness, and 68% of the 75 patients whose spinal imaging was reported showed signal changes in the spinal cord on magnetic resonance imaging. An earlier systematic review of case reports by Garakani and colleagues (2016) found 91 cases in 77 publications, of which 72 had neurological effects, along with 11 publications reporting 29 deaths related to nitrous oxide. A 2022 systematic review by Marsden and colleagues, of 24 case series and 91 case reports, described a similar pattern: the people affected were typically in their twenties and had used large amounts daily for several months, and sensory change, gait disturbance and weakness were characteristic (Marsden et al., 2022). All three reviews draw on case reports and case series, so research on how often recreational use causes harm is still evolving. Health Canada (2025c) warned in 2025 that repeated use may result in lasting neurological damage, including permanent paralysis in severe cases, even after a person stops.
Oussalah and colleagues (2019) found that 80% of 100 published patients with nitrous oxide toxicity had tingling or numbness. A news story reports this as “80% of people who use nitrous oxide get nerve damage.” In three or four sentences, explain why the claim does not follow from the evidence. Think about who is included in a collection of published case reports, what the denominator of the 80% is, and what kind of study would be needed to estimate how often nerve damage occurs among people who use nitrous oxide.
7.6 Reported Trends: Europe and Canada
In November 2022 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, now the European Union Drugs Agency) published a rapid communication describing recreational nitrous oxide use as a growing concern for Europe. It reported that small 8-gram cartridges are cheap and easy to buy, that suppliers had begun selling large 15 kilogram cylinders aimed at the recreational market, which make the gas cheaper and appear to encourage heavier and more regular use, and that social media plays a role in advertising and sales in some areas (EMCDDA, 2022). It also stated that the large majority of people do not use nitrous oxide and that most who do use small amounts infrequently. It reported that poisoning cases had risen as use grew, as Table 4.7 shows.
Table 4.7. Nitrous oxide poisoning cases reported to poison centres in three European countries (EMCDDA, 2022).
| Country | Earlier year | Later year | Approximate increase |
|---|---|---|---|
| Denmark | 16 cases (2015) | 73 cases (2021) | About 4.6 times |
| France | 10 cases (2017) | 134 cases (2020) | About 13 times |
| Netherlands | 13 cases (2015) | 144 cases (2020) | About 11 times |
The EMCDDA linked many of the cases since 2017 to neurotoxicity caused by irreversible inactivation of vitamin B12, reported frostbite and lung injuries, and noted that car crashes involving the gas had increased significantly in at least one country, the Netherlands (EMCDDA, 2022). Poison centre counts depend on how many people call and on awareness among clinicians, so part of any increase can reflect better recognition; the authors interpreted the rise as accompanying growth in heavier use. The box below summarizes how Health Canada responded in 2025.
Health Canada’s 2025 advisory on nitrous oxide
On 6 June 2025, Health Canada warned Canadians not to inhale nitrous oxide for recreational purposes, and it updated the advisory on 20 November 2025 with further products. The advisory lists loss of consciousness and, in some cases, death; vitamin B12 deficiency and anemia; nerve damage, spinal cord degeneration and, in severe cases, permanent paralysis; and other harms including asphyxia and heart problems. It states that products sold for recreational inhalation are unauthorized drugs that Health Canada has not reviewed for safety, efficacy or quality, and that the department had seized products and worked with the Canada Border Services Agency to stop shipments (Health Canada, 2025c). The advisory gave no national figures on how many people use nitrous oxide, so it does not show how common use is in Canada.
The European and Canadian responses share a pattern that later lessons examine: restricting supply and providing targeted health information for a product with many legitimate uses. The EMCDDA (2022) stressed that any response must account for industrial, medical and consumer uses and called for better monitoring and research. Lesson 11 develops how drugs come to be controlled, and HSCI 402 develops prevention and surveillance.
Summary and Transition
Inhalants are vapours from everyday products, grouped as volatile solvents, aerosols, gases and nitrites. Most act as central nervous system depressants through GABA-A and NMDA receptors and produce a brief intoxication that resembles drunkenness. A single episode can kill through sudden sniffing death, asphyxiation, suffocation or injury, and repeated solvent use damages the brain, nerves and other organs. Nitrous oxide blocks NMDA receptors and, with heavy use, inactivates vitamin B12, which can cause spinal cord and nerve damage; a 2022 European report described rising recreational use and poisonings, and Health Canada warned against it in 2025. Section 4 returns to the depressants as a group and asks why their combination, above all with opioids, is so dangerous for breathing.
Key Takeaways
- 7.1 Inhalants are vapours from products made for other purposes, grouped by NIDA as volatile solvents, aerosols, gases and nitrites; nitrites stand apart because they widen blood vessels rather than depress the central nervous system. In Canada, as of July 2026, most inhalants are lawful consumer products outside the CDSA schedules, while nitrous oxide for inhalation is regulated as a drug that only authorized professionals may administer.
- 7.2 Volatile solvents act like other depressants, as positive modulators of GABA-A receptors, and toluene and several other solvents also block NMDA receptors; in rats, toluene raises dopamine in reward pathways. The result is a brief intoxication that resembles drunkenness, because the vapours enter and leave the brain rapidly.
- 7.3 A single episode of inhalant use can kill through sudden sniffing death, a fatal heart rhythm disturbance linked particularly to butane, propane and aerosols, or through asphyxiation, suffocation, choking, seizures, injuries and burns.
- 7.4 Repeated solvent use damages the brain’s white matter, peripheral and optic nerves, hearing, and the heart, liver, kidneys and bone marrow. Early inhalant use is linked to later drug use, but it may mark young people already facing many difficulties rather than cause later problems.
- 7.5 Nitrous oxide blocks NMDA receptors, and heavy use oxidizes the cobalt in vitamin B12, producing a functional deficiency that can cause subacute combined degeneration of the spinal cord, myelopathy and polyneuropathy. Collections of published cases describe symptoms among people already harmed and cannot show how often harm occurs among everyone who uses the gas.
- 7.6 A 2022 European report described rises in recreational nitrous oxide use and poison centre cases in several European countries, and Health Canada warned against recreational inhalation in 2025. Poison centre counts depend on who calls and on clinicians’ awareness and have no denominator of people who use the gas, so they show a trend in reported cases rather than the risk of each use.
Reflection
Health Canada’s advisory of 6 June 2025 warned Canadians not to inhale nitrous oxide recreationally. The European Monitoring Centre for Drugs and Drug Addiction (2022) reported that poison centre cases in the Netherlands rose from 13 in 2015 to 144 in 2020, while stating that most people who use the gas use small amounts infrequently. Write a short, accurate and non-sensational health message about nitrous oxide for university students that explains how heavy use damages nerves, who is at greatest risk, and why some harms can occur in a single session. Then explain one limit of the poison centre data.
Message. Nitrous oxide, the gas in whipped-cream chargers, is a medical anesthetic, and Health Canada stated in 2025 that selling it for recreational inhalation is not authorized. Heavy or frequent use is the main concern. The gas oxidizes the cobalt in vitamin B12, so the vitamin stops working even if your diet is good, and the enzyme methionine synthase fails. Over time this can damage the spinal cord and nerves, causing tingling or numbness, an unsteady walk and weakness, and in severe cases lasting paralysis. Among 100 published patients, the median age was 27 and more than half had used the gas recreationally. Some harms do not depend on heavy use: the gas can displace oxygen and cause loss of consciousness, cold gas from pressurized containers can cause frostbite, and a 2022 European report noted that car crashes involving the gas had increased in at least one country. Anyone with numbness or trouble walking after using nitrous oxide should seek medical care promptly.
Limit of the data. Poison centre counts depend on who calls and on how well clinicians recognize nitrous oxide toxicity. A tenfold rise could partly reflect greater awareness and reporting. The counts also have no denominator of people who use the gas, so they cannot show how risky each use is, only that more cases were reported as use grew.
Minimum 20 characters required.
Question 1: Which inhalant group acts mainly by widening blood vessels and relaxing muscles, unlike the others?
Question 2: What is sudden sniffing death?
Question 3: How does heavy nitrous oxide use damage the spinal cord and nerves?
Question 4: Oussalah and colleagues (2019) found tingling or numbness in 80% of 100 published patients with nitrous oxide toxicity. What does this figure describe?
Combining Depressants: Breathing, Overdose and Prescribing
Content note
This section discusses overdose deaths. If you would like support, the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8), the National Overdose Response Service for people who use drugs alone (1-888-688-6677) and the Hope for Wellness Help Line for Indigenous people (1-855-242-3310) are available at any time.
Introduction
The first three sections treated each depressant on its own. People rarely encounter them that way. A person may take a sleeping pill after a few drinks, be prescribed an opioid for pain and a benzodiazepine for anxiety, or use drugs from an unregulated supply in which opioids and benzodiazepine-type drugs are mixed. The United States National Institute on Alcohol Abuse and Alcoholism warns that combining alcohol with opioids can cause an overdose even at moderate levels of alcohol, and that combining it with sleep medicines or benzodiazepines also increases the risk of overdose (NIAAA, 2025). This section explains why, using the physiology of breathing, laboratory experiments, studies of whole populations and two prescribing rules that grew out of this evidence. Opioids themselves are the subject of Lesson 5, which develops their receptors, the toxic drug supply and naloxone.
Learning Objectives
- 8.1 Explain how breathing is controlled and how alcohol, benzodiazepines, GHB and opioids each interfere with it.
- 8.2 Distinguish additive from synergistic effects and pharmacodynamic from pharmacokinetic interactions.
- 8.3 Interpret experimental evidence on combined depressants, including the strengths and limits of a controlled crossover experiment.
- 8.4 Interpret population evidence on combined depressants, including the strengths and limits of observational studies.
- 8.5 Summarize the risks of combining GHB, alcohol and sleep medicines and the evidence behind each common depressant combination.
- 8.6 Describe the 2016 United States boxed warning and British Columbia’s practice standard on prescribing opioids and sedatives.
- 8.7 Apply the pharmacology of this lesson to the provisions of a real Canadian prescribing standard.
8.1 How Breathing Is Controlled and How Depressants Interfere
Breathing is mostly automatic. Groups of neurons in the brainstem set the rhythm of each breath and adjust it to the body’s needs, above all to the level of carbon dioxide in the blood: when carbon dioxide rises, a healthy person breathes faster and more deeply. Researchers measure this reflex as the hypercapnic ventilatory response, the amount of air a person breathes per minute when the carbon dioxide level is deliberately raised (van der Schrier et al., 2017). Two other protections matter in an overdose: arousal, the ability to wake up when breathing falters, and protective reflexes such as the gag reflex that keep the airway clear.
Different drugs reach the same outcome. Each depressant in this lesson weakens one or more of these protections. Alcohol poisoning shuts down the brain areas that control breathing, heart rate and body temperature, and its warning signs include slow or irregular breathing, inability to wake and a missing gag reflex (NIAAA, 2025). Opioids act directly on the respiratory control centres of the brainstem (Pattinson, 2008). Benzodiazepines depress spontaneous breathing, an effect that is enhanced dramatically and in a dose-dependent way when they are given with opioids (Griffin et al., 2013). GHB produces impaired consciousness and coma with only small increases in dose (EMCDDA, 2008). Figure 4.6 shows how drugs that act on different receptors converge on the same physiological targets.
8.2 How Depressants Combine
Because these drugs converge on the same protections, the way their effects combine matters as much as what each does alone.
8.2.1 Additive and Synergistic Effects
When two drugs with similar effects are combined, the result can be additive, equal to the sum of their separate effects, or synergistic, greater than that sum. Griffin and colleagues (2013) describe opioids, alcohol and over-the-counter sleep aids as having additive or synergistic effects with benzodiazepines on the central nervous system and on breathing. Either way, the combination can cross a dangerous threshold that neither drug would reach alone. Convergence also limits the protection that tolerance offers. Lesson 3 introduced cross-tolerance between drugs acting on the same receptor; because an opioid and a benzodiazepine depress breathing through different receptors, tolerance built up to one need not protect a person from the other.
8.2.2 Two Kinds of Interaction
Drug interactions come in two broad kinds. A pharmacokinetic interaction occurs when one drug changes the amount of another in the body, as when chronic drinking induces the CYP2E1 enzyme and alters how some medicines are broken down (Section 1). A pharmacodynamic interaction occurs when two drugs act together on the same body system without necessarily changing each other’s levels. The interactions in this section are mainly pharmacodynamic. When volunteers took GHB with alcohol, for example, the peak GHB level was 16% higher and its half-life 29% longer than without alcohol, but neither difference was statistically significant, and the alcohol levels were unchanged (Busardò & Jones, 2015). The danger of the combination lies in what the two drugs do together at their targets. The next part examines how researchers have measured that danger.
8.3 Evidence from a Laboratory Experiment
Testing a dangerous combination in people requires great care. Case 4.2 describes one experiment, published in 2017, that did so under close monitoring.
Van der Schrier and colleagues (2017) studied 12 young (21 to 28 years) and 12 older (66 to 77 years) volunteers who had not been using opioids. In three sessions, each took a 20 mg tablet of the opioid oxycodone together with an intravenous infusion of alcohol set to produce a blood alcohol of 0, 0.5 or 1 gram per litre (0, 50 or 100 milligrams per 100 millilitres). Oxycodone alone reduced resting breathing by 28%, and alcohol at 1 gram per litre reduced it by a further 19%. Breathing measured at a raised carbon dioxide level fell from 33.4 litres per minute without drugs to 18.6 with oxycodone and 15.7 with oxycodone plus the higher alcohol level. Pauses in breathing (apneic events) became more frequent with the combination, with up to 11 recorded in a six-minute window, and the older volunteers were more affected than the younger ones. The authors concluded that alcohol together with oxycodone causes greater depression of breathing than either alone, to a clinically relevant degree.
The study is persuasive because each volunteer received all three conditions and so served as their own comparison (a crossover design), and because it measured breathing directly. Its limits are equally clear. The doses were modest and controlled, the volunteers were healthy and closely monitored, and the alcohol levels were around Canada’s Criminal Code driving limit (Section 1). Real overdoses involve higher doses, unknown drug contents and no monitoring, so experiments of this kind show the mechanism, and population studies are needed to show its consequences.
8.4 Evidence from Populations
Population studies cannot assign drugs at random, but they can follow very large numbers of people and record deaths. Case 4.3 describes one such study of benzodiazepine co-prescribing, published in 2015.
Park and colleagues (2015) studied United States veterans who received opioid pain medicines through the Veterans Health Administration from 2004 to 2009. They compared all 2,400 veterans who died of a drug overdose while receiving opioids with a random sample of 420,386 veterans who also received opioids, a design called a case-cohort study. During the study period, 27% of veterans receiving opioids were also prescribed benzodiazepines, and about half of the overdose deaths (1,185) occurred while veterans were prescribed both. Compared with veterans with no benzodiazepine prescription, the adjusted hazard ratio for overdose death was 2.33 (95% confidence interval 2.05 to 2.64) for those with a former prescription and 3.86 (3.49 to 4.26) for those with a current one, and the risk rose as the daily benzodiazepine dose increased.
A hazard ratio compares the rate at which an event occurs in two groups over time; a value of 3.86 means that veterans currently prescribed a benzodiazepine died of overdose at nearly four times the rate of those without one, after adjustment for other measured factors. Because the study was observational, some of that difference could reflect confounding: people prescribed both drugs may have had more severe pain, mental illness or other conditions that independently raised their risk. Two features make a causal role for the combination more credible. The risk rose with the benzodiazepine dose, and the laboratory evidence in Case 4.2 and the physiology in 8.1 How Breathing Is Controlled and How Depressants Interfere supply a plausible mechanism. Across studies, a 2020 review by Boon and colleagues of 29 publications found that combined use of opioids and benzodiazepines raised the risk of death and severe breathing problems in most of the clinical and non-clinical settings examined, while noting that the balance of harm and benefit depends on the setting, as in hospice care, where benefits may outweigh the risks (Boon et al., 2020). HSCI 402 develops these methods for judging causation.
Other studies track trends in co-involvement, counting how often depressants appear together in overdose deaths. In the United States, the share of deaths involving opioid pain medicines that also involved benzodiazepines rose from 18% in 2004 to 31% in 2011 (FDA, 2016b). Across all opioid overdose deaths in the United States, benzodiazepine co-involvement rose from 8.7% in 1999 to 21.0% in 2017, and alcohol co-involvement from 12.4% to 14.7% (Tori et al., 2020). In Canada, Mocanu and colleagues (2024) reviewed all 11,033 death investigations in Ontario from 2017 to 2021 in which post-mortem toxicology found an opioid, and found a benzodiazepine in 54.5%. The most common was etizolam, a benzodiazepine-type drug, and benzodiazepine detections with opioids grew faster than opioid detections overall, which the authors linked to an increasingly toxic drug supply. Lesson 5 develops how such sedative adulterants entered the toxic drug supply. Use Interactive 4.2 to compare these sources.
Data explorer: depressants combined
Choose a data source to see its results as a chart, with a note on how to read it and a question to consider. All values are taken from the studies cited.
8.5 GHB, Alcohol and Sleep Medicines
The combinations that cause concern extend beyond opioids. GHB has a steep dose-response curve, and its toxic effects may intensify when it is combined with alcohol and other psychoactive substances (EMCDDA, 2008); with a fatal dose perhaps only five to eight times a recreational dose, there is little margin for an added depressant (Busardò & Jones, 2015). Alcohol taken with Z-drugs or benzodiazepines increases the risk of overdose (NIAAA, 2025). Table 4.8 summarizes the main combinations and the evidence for each.
Table 4.8. Common depressant combinations, the reason their risks rise, and the evidence discussed in this lesson.
| Combination | Why risk rises | Evidence |
|---|---|---|
| Alcohol and an opioid | Both reduce the drive to breathe; alcohol adds to the opioid’s effect | Experiment (van der Schrier et al., 2017); death data (Tori et al., 2020); NIAAA (2025) |
| Benzodiazepine and an opioid | Benzodiazepine depression of breathing is enhanced dramatically by opioids | Review (Griffin et al., 2013); case-cohort (Park et al., 2015); trends (FDA, 2016b); Ontario toxicology (Mocanu et al., 2024) |
| Alcohol and a benzodiazepine or Z-drug | Additive or synergistic depression of the central nervous system | Review (Griffin et al., 2013); NIAAA (2025) |
| GHB and alcohol | Steep GHB dose-response leaves little margin for a second depressant | EMCDDA (2008); Busardò and Jones (2015) |
For prescribers, the most controllable of these combinations is the one they create themselves when they prescribe an opioid and a sedative to the same person. The final part of the section examines how regulators and professional bodies have responded.
8.6 What This Means for Prescribing
Evidence on combined depressants has changed prescribing rules in both the United States and Canada. The two responses described here differ in form: one is a warning on a drug’s label, and the other is a professional standard that physicians must follow.
8.6.1 The 2016 Boxed Warning in the United States
On 31 August 2016, the United States Food and Drug Administration (FDA) required boxed warnings and patient medication guides on nearly 400 products: opioid pain medicines, opioid cough medicines and benzodiazepines. The warnings describe the serious risks of using these medicines together, including extreme sleepiness, respiratory depression, coma and death (FDA, 2016a). The FDA’s accompanying safety communication reported that the proportion of people prescribed opioid pain medicines who also had an overlapping benzodiazepine prescription had risen by 41% between 2002 and 2014, and it advised health care professionals to limit prescribing the two together to patients for whom alternative treatments are inadequate and to keep doses and duration to the minimum possible (FDA, 2016b).
8.6.2 British Columbia’s Practice Standard
In Canada, the College of Physicians and Surgeons of British Columbia (CPSBC) set a practice standard, Safe Prescribing of Opioids and Sedatives, which took effect on 1 June 2016 and, as of October 2026, was most recently revised on 1 April 2026 (version 5.0). The College calls the physicians and surgeons it regulates “licensees”. The box below summarizes the provisions that relate to this lesson.
Selected provisions of the CPSBC standard Safe Prescribing of Opioids and Sedatives
- The standard covers opioids, benzodiazepines (including the Z-drugs zopiclone and zolpidem) and other sedative-hypnotics such as barbiturates, and excludes active cancer care, palliative care and the treatment of substance use disorders.
- It states that co-prescribing medications such as benzodiazepines, sedatives and opioids significantly compounds the risk of death due to overdose, and that if long-term treatment with both is considered, the licensee must taper and discontinue one of them after making all efforts to involve the patient in the decision.
- Licensees who prescribe opioids or sedatives must document their advice to patients to avoid other central nervous system and respiratory depressants, including alcohol, cannabis and some over-the-counter medications.
- Licensees must review the patient’s medication profile and consult PharmaNet, British Columbia’s province-wide record of dispensed prescriptions, where it is available, before prescribing, and must fully inform patients of the risks and benefits when starting treatment.
- Medications such as benzodiazepines and opioids must not be abruptly discontinued and must be tapered slowly; the standard also notes that elderly patients are particularly vulnerable.
- Licensees must not exclude or dismiss patients from their practice because of their current use of, or request for, opioids or sedatives.
Source: CPSBC (2026), version 5.0.
8.7 Applying the Pharmacology to the Standard
Read together, the provisions balance two dangers that this lesson has described. The pharmacology of 8.1 to 8.4 supports reducing co-prescribing, while the withdrawal pharmacology of Section 2 explains why the standard insists that reductions be slow and that patients not be abandoned. A rule that removed a long-term benzodiazepine abruptly could trade one danger for another, and a patient dismissed from care might turn to an unregulated supply in which, as the Ontario data show, opioids and benzodiazepine-type drugs often appear together. The deprescribing evidence in Section 2, including the EMPOWER trial and the 2025 reviews, suggests one way to reduce co-prescribing while keeping patients involved. Lesson 5 explains what naloxone can and cannot reverse when sedatives are present, and HSCI 402 develops naloxone programs and overdose response.
The College of Physicians and Surgeons of British Columbia’s practice standard Safe Prescribing of Opioids and Sedatives (effective 1 June 2016 and, as of October 2026, last revised 1 April 2026) includes the provisions summarized in the box under 8.6.2 British Columbia’s Practice Standard. Use what you have learned in this lesson to complete three tasks.
- For the provision that co-prescribing benzodiazepines, sedatives and opioids significantly compounds the risk of overdose death, write two or three sentences explaining the physiology behind it, citing at least one piece of experimental evidence (Case 4.2) and one piece of population evidence (Case 4.3).
- For the provision that benzodiazepines must not be abruptly discontinued, explain the neuroadaptation involved, using the description of withdrawal in Section 2, and name one serious withdrawal effect.
- The standard notes that elderly patients are particularly vulnerable but sets no separate rules for them. Using the results of van der Schrier and colleagues (2017), the half-life findings of Klotz and colleagues (1975) and the EMPOWER trial, write a short paragraph recommending how a clinic in British Columbia might apply the standard to patients aged 65 and older who take both an opioid and a benzodiazepine.
Summary and Lesson Close
Depressants that act on different receptors converge on the brainstem drive to breathe, on arousal and on protective reflexes, so their effects add up or exceed the sum of their parts. A controlled experiment showed alcohol deepening oxycodone’s depression of breathing, especially in older adults; a large case-cohort study linked current benzodiazepine prescriptions to nearly four times the rate of overdose death among veterans receiving opioids; toxicology from Ontario found benzodiazepine-type drugs in more than half of opioid-positive deaths from 2017 to 2021; and a 2020 review found higher risks with combined use in most of the settings it examined. These findings led to the 2016 United States boxed warning and to British Columbia’s prescribing standard, which pairs limits on co-prescribing with slow tapering and continued care. The reflection and final assessment that follow ask you to bring together the pharmacology of alcohol, sedative-hypnotics, inhalants and their combinations. Lesson 5 then turns to the opioids and the toxic unregulated drug supply.
Key Takeaways
- 8.1 Breathing depends on the brainstem drive to breathe, set largely by carbon dioxide, on arousal when breathing falters and on protective reflexes such as the gag reflex. Alcohol, opioids, benzodiazepines and GHB act on different receptors but each weakens one or more of these protections.
- 8.2 Combined depressants can be additive, equal to the sum of their effects, or synergistic, greater than that sum, and tolerance to one drug need not protect against another that acts on a different receptor. The main danger is pharmacodynamic, the drugs acting together on breathing, rather than pharmacokinetic, one drug changing the level of another.
- 8.3 In a crossover experiment, alcohol deepened oxycodone’s depression of breathing and increased pauses in breathing, especially in older volunteers. The design shows the mechanism without confounding, but its modest doses, healthy monitored volunteers and small sample limit what it says about real overdoses.
- 8.4 Among United States veterans receiving opioids, a current benzodiazepine prescription was linked to nearly four times the rate of overdose death, with risk rising with dose, and toxicology from Ontario found a benzodiazepine in more than half of opioid-positive deaths from 2017 to 2021. Observational studies show consequences at scale, but confounding limits a causal reading, which dose-response and a plausible mechanism help to strengthen.
- 8.5 GHB’s steep dose-response curve leaves little margin for alcohol or another depressant, and alcohol taken with Z-drugs or benzodiazepines raises the risk of overdose. Each common combination is supported by experimental, review or population evidence.
- 8.6 In 2016 the FDA required boxed warnings on nearly 400 opioid and benzodiazepine products and advised limiting their combined use. British Columbia’s practice standard requires tapering one drug when long-term co-prescribing is considered, checking PharmaNet, slow tapering rather than abrupt discontinuation, and never dismissing patients for their use of these drugs.
- 8.7 Applying the lesson’s pharmacology to the standard shows how it balances two dangers: combined depression of breathing supports reducing co-prescribing, while withdrawal pharmacology explains why reductions must be slow and patients kept in care. Patient-centred deprescribing, as in EMPOWER, offers one way to do both.
Reflection
In Park and colleagues’ (2015) case-cohort study of United States veterans receiving opioid pain medicines, those with a current benzodiazepine prescription had an adjusted hazard ratio of 3.86 for overdose death compared with those without one, and the risk rose with the benzodiazepine dose. In van der Schrier and colleagues’ (2017) crossover experiment with 24 healthy volunteers, adding alcohol at 1 gram per litre to 20 mg of oxycodone reduced breathing at a raised carbon dioxide level from 18.6 to 15.7 litres per minute. Explain why the two studies together make a stronger case that combining depressants is dangerous than either study alone, identifying one weakness of each design that the other helps to address.
The two studies answer different questions. Park and colleagues counted real deaths among more than 400,000 veterans and found that a current benzodiazepine prescription was linked to nearly four times the rate of overdose death. That shows the outcome that matters, in ordinary practice, at a large scale. Its weakness is confounding: veterans prescribed both drugs may have had more severe pain, mental illness or other conditions that raised their risk independently, and an observational study cannot rule this out completely, although the dose-response pattern helps.
Van der Schrier and colleagues controlled the doses and gave every volunteer each condition, so differences in breathing could not be explained by who received which drug. That design removes confounding and shows a mechanism, since breathing fell further when alcohol was added to oxycodone, especially in older volunteers. Its weaknesses are the small sample, modest doses, a different depressant from the veterans study, and an outcome (breathing at a raised carbon dioxide level) that stands in for overdose death.
Together they cover each other’s gaps. The experiment supplies a plausible mechanism and shows that the effect is not an artefact of who gets prescribed what, and the population study suggests that the mechanism translates into deaths at scale. This combination of mechanism, dose-response and consistency is the kind of evidence on which regulators such as the FDA acted in 2016.
Minimum 20 characters required.
Question 1: Why can an opioid and a benzodiazepine together depress breathing more than either alone, even in a person tolerant to opioids?
Question 2: In van der Schrier and colleagues’ (2017) experiment, breathing at a raised carbon dioxide level was 33.4 L/min with no drugs, 18.6 with oxycodone and 15.7 with oxycodone plus alcohol at 1 g/L. Which conclusion fits?
Question 3: Park and colleagues (2015) reported an adjusted hazard ratio of 3.86 for overdose death with a current benzodiazepine prescription. Which concern most limits a causal reading of this result?
Question 4: Which provision appears in the CPSBC practice standard Safe Prescribing of Opioids and Sedatives, as revised in April 2026?
Final Assessment
Bringing It All Together
This lesson has followed one idea through four groups of drugs: depressants slow the central nervous system, and the same slowing that relieves anxiety, eases sleep or produces intoxication can, at higher doses or in combination, stop a person breathing. Alcohol showed the pharmacology in its most familiar form, acting on GABA-A and NMDA receptors, absorbed fastest from the small intestine, dissolved in body water and removed by the liver at a roughly constant amount per hour. The Canadian standard drink and the Widmark formula turned those facts into a way of measuring dose, and Canada’s 2023 guidance turned the evidence on harm into a continuum of risk that people can use.
The sedative-hypnotics act on the same GABA-A receptor in different ways, which explains why barbiturates were so much more dangerous than the benzodiazepines that replaced them, and why GHB, acting through GABA-B with a steep dose-response curve, has so narrow a margin. Half-life, tolerance and physical dependence explain why sedatives prescribed for sleep are often continued for years, why stopping them must be gradual, and how deprescribing might be supported, as the 2014 EMPOWER trial in Quebec illustrated, although 2025 reviews rated the wider evidence as uncertain. Inhalants added a group of depressants drawn from household products, with acute dangers in a single session and, for nitrous oxide, a distinctive form of nerve damage through vitamin B12.
The final section brought the groups together. Because depressants converge on the drive to breathe, arousal and protective reflexes, their combinations are more dangerous than any one drug, a finding supported by the experiment, the population studies and the Ontario toxicology data in this lesson and by a 2020 review, and reflected in the 2016 FDA boxed warning and British Columbia’s prescribing standard.
Key Takeaways from this lesson
- Alcohol is a central nervous system depressant that enhances GABA-A receptor function and inhibits NMDA glutamate receptors, with many other targets.
- Alcohol is absorbed fastest from the small intestine, dissolves in body water and is removed by the liver at a roughly constant amount per hour, about 15 mg per 100 mL on average, so food, body water, medicines and liver disease make blood alcohol differ between people.
- A Canadian standard drink contains 17.05 mL or 13.45 g of pure alcohol, and container size and strength can make one serving equal to two or more standard drinks. The Widmark formula estimates blood alcohol from dose, body weight, a body-water factor and elimination, but every estimate carries wide uncertainty.
- Canada’s Guidance on Alcohol and Health (2023) communicates risk on a continuum based on explicit lifetime risk thresholds, and its expert panel proposed standard-drink labelling.
- Benzodiazepines boost GABA’s effect at the GABA-A receptor, while barbiturates can open the channel directly, which gives barbiturates a much narrower margin of safety. GHB acts mainly through GABA-B receptors, has a steep dose-response curve and a short half-life, and, as of July 2026, is in Schedule I of the CDSA, while its medical form, sodium oxybate, treats cataplexy.
- Regular sedative use produces tolerance and physical dependence, so withdrawal should be a slow taper, and patient-directed deprescribing reduced benzodiazepine use in older adults in the 2014 EMPOWER trial, although 2025 reviews rated the wider evidence as uncertain.
- Inhalants can kill in a single session through sudden sniffing death, asphyxiation or injury, and heavy nitrous oxide use inactivates vitamin B12 and can damage the spinal cord.
- Depressants combined, especially with opioids, depress breathing more than any one drug, which led to the 2016 FDA boxed warning and British Columbia’s standard on prescribing opioids and sedatives.
Core Concepts Reviewed
Section 1: GABA-A and NMDA receptors, absorption and first-pass metabolism, alcohol dehydrogenase and acetaldehyde, zero-order elimination, the Canadian standard drink, blood alcohol concentration, the Widmark formula and risk communication in Canada’s 2023 guidance.
Section 2: benzodiazepines, Z-drugs, barbiturates and GHB, binding sites on the GABA-A receptor, therapeutic index, half-life and accumulation, tolerance, physical dependence, abrupt withdrawal, deprescribing and the number needed to treat.
Section 3: volatile solvents, aerosols, gases and nitrites, solvent actions at GABA-A and NMDA receptors, sudden sniffing death, long-term solvent harms, nitrous oxide and vitamin B12, and reported trends and responses.
Section 4: control of breathing, additive and synergistic effects, pharmacodynamic and pharmacokinetic interactions, experimental and population evidence, confounding, and the 2016 FDA boxed warning and CPSBC prescribing standard.
Before the final assessment, take a few minutes to connect the pharmacology of depressants to the ways health systems communicate risk and change prescribing.
Reflection
British Columbia’s College of Physicians and Surgeons requires physicians to taper and discontinue one drug when long-term co-prescribing of an opioid and a sedative is considered, while also forbidding abrupt discontinuation and the dismissal of patients who use these drugs. Canada’s Guidance on Alcohol and Health (2023), by contrast, is advice that relies on people understanding standard drinks. Drawing on all four sections of this lesson, reflect on how knowledge of depressant pharmacology (receptors, absorption and elimination, half-life, tolerance and dependence, and combined effects) should shape the way health systems communicate risk and change prescribing. Give at least one example involving alcohol and one involving sedative medicines.
Depressant pharmacology points to three lessons for health systems. First, dose is hard for people to judge. Alcohol’s blood level depends on body water, food and a liver that removes a fixed amount each hour, so the same three drinks can produce very different levels in two people. Communication therefore has to supply a usable unit. Canada’s 2023 guidance does this by expressing risk in standard drinks on a continuum, and its expert panel suggested that standard-drink labelling could be a particularly effective change, because working out the standard drinks in a 473 mL can at the point of purchase takes information people may not have.
Second, regular use changes the brain. Tolerance to the sleep effect of benzodiazepines develops within weeks, while physical dependence makes stopping risky, and long half-lives in older adults mean effects build up and fade over days. Prescribing change must therefore be gradual. The CPSBC standard’s ban on abrupt discontinuation and the results of patient education in the 2014 EMPOWER trial show one way a system might reduce harmful prescribing without abandoning patients.
Third, depressants converge on breathing through different receptors, so combinations are more dangerous than either drug and tolerance to one need not protect against another. That justifies rules that target combinations specifically, such as the 2016 FDA boxed warning and the BC standard. It also implies that prescribing rules alone cannot address combinations that arise from an unregulated supply, as the Ontario toxicology data show, which is where the harm reduction approaches of HSCI 402 become relevant.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: Alcohol, benzodiazepines and barbiturates share one main receptor target. Which statement describes it and GHB’s main target?
Question 2: Which feature of alcohol’s pharmacokinetics differs from most drugs described by a half-life?
Question 3: A hypothetical person drinks two 473 mL tall cans of beer at 5% alcohol. About how many Canadian standard drinks is this?
Question 4: A hypothetical 70 kg person with a Widmark factor of 0.68 drinks four standard drinks (53.8 g of alcohol). With elimination of 15 mg per 100 mL per hour, what is the Widmark estimate three hours after drinking began?
Question 5: Which choice in Canada’s Guidance on Alcohol and Health (2023) most directly puts risk information where people make decisions about drinking?
Question 6: Canada’s Guidance on Alcohol and Health places the boundary of low risk at two standard drinks per week. On what was this boundary based?
Question 7: Which observation best explains why some people keep taking a benzodiazepine sleeping pill for years?
Question 8: Which statement about legal status in Canada, as of July 2026, is correct?
Question 9: According to Ashton (2002), why is abrupt withdrawal from long-term, high-dose benzodiazepine use dangerous?
Question 10: A product is described as a liquid that turns to vapour at room temperature, such as paint thinner. Which category and main action fit it?
Question 11: Why does Health Canada’s 2025 advisory treat nitrous oxide products sold for recreational inhalation as unauthorized?
Question 12: For which combination in Table 4.8 did this lesson describe an experiment that measured breathing directly in volunteers?
Question 13: Mocanu and colleagues (2024) found a benzodiazepine in 54.5% of opioid-positive death investigations in Ontario from 2017 to 2021. Which interpretation does the study support?
Question 14: Which pair correctly contrasts a pharmacokinetic and a pharmacodynamic interaction from this lesson?
Question 15: The CPSBC standard requires tapering one drug when long-term co-prescribing of an opioid and a sedative is considered, but forbids abrupt discontinuation. Which finding from this lesson best explains the second rule?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
Definitions of the terms, drugs, frameworks and people introduced in this lesson on alcohol and other depressants.